Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epcoritamab Plus Chemotherapy and AutoHCT in R/R LBCL
NCT06905509Phase 2Recruiting
- Sponsor
- University of California, Davis
- Start
- Jul 2025
- Primary completion
- Jul 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of epcoritamab in diffuse large B-cell lymphoma (DLBCL), sponsored by University of California, Davis. Started Jul 2025; status: recruiting.
02
Drugs
epcoritamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06905509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06905509.